Teenagers Can Join COVID-19 Vaccine Study

Moderna Inc. launched the TeenCove vaccine study on December 2, 2020. This phase 2/3 clinical trial of about 3,000 adolescents will evaluate the safety, reactogenicity, and effectiveness of the experimental mRNA-1273 vaccine candidate in participants 12 to <18 years old to prevent COVID-19, which is caused by an infection from the SARS-CoV-2 virus.

The mRNA-1273 vaccine will be administered in 2-doses, 28 days apart to this adolescent population. 

The NCT04649151 study's estimated completion date is June 30, 2022.